• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
ProStrakan Group plc - Product Pipeline Review - 2012 Product Image

ProStrakan Group plc - Product Pipeline Review - 2012

  • Published: July 2012
  • 89 pages
  • Global Markets Direct

ProStrakan Group plc – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “ProStrakan Group plc - Product Pipeline Review - 2012” provides data on the ProStrakan Group plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ProStrakan Group plc’s corporate website, SEC filings, investor presentations and featured press releases, both from ProStrakan Group plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ProStrakan Group plc - Brief ProStrakan Group plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ProStrakan Group plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, READ MORE >

2
List of Tables 5
List of Figures 6
ProStrakan Group plc Snapshot 7
ProStrakan Group plc Overview 7
Key Information 7
Key Facts 7
ProStrakan Group plc – Research and Development Overview 8
Key Therapeutic Areas 8
ProStrakan Group plc – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
ProStrakan Group plc – Pipeline Products Glance 12
ProStrakan Group plc – Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
ProStrakan Group plc Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
ProStrakan Group plc – Drug Profiles 14
Abstral 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Sancuso 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
SyB D-0701 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Testosterone-Glucoside 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ProStrakan Group plc – Pipeline Analysis 19
ProStrakan Group plc – Pipeline Products by Therapeutic Class 19
ProStrakan Group plc – Pipeline Products By Target 21
ProStrakan Group plc – Pipeline Products by Route of Administration 22
ProStrakan Group plc – Pipeline Products By Mechanism of Action 23
ProStrakan Group plc – Recent Pipeline Updates 24
ProStrakan Group plc - Dormant Projects 26
ProStrakan Group plc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
ProStrakan Group plc, Recent Developments 28
ProStrakan Group plc- Press Release 28
May 25, 2012: Orexo Receives €3.3m Milestone Payment From ProStrakan 28
Apr 26, 2012: ProStrakan’s Sancuso Receives Marketing Authorization Approval in Europe 28
Mar 16, 2012: Aptalis Pharma Begins Promotion Of RECTIV To Physicians In US 29
Feb 16, 2012: CHMP Adopts Positive Opinion Recommending Marketing Authorization For ProStrakan's Sancuso 29
Oct 21, 2009: ProStrakan Announces FDA Acceptance of US Submission of Cellegesic (Nitroglycerin) 0.4% Ointment 30
Sep 06, 2009: ProStrakan Announces FDA Acceptance Of Abstral Filing in the US 31
Aug 06, 2009: Abstral file submitted to the FDA for approval in the USA 31
Jul 24, 2009: Orexo Announces Positive Phase III Results For KW-2246 In Japan 31
Jun 30, 2009: Orexo announces that Abstral is ready for launch in France 32
Jun 30, 2009: Orexo Announces That Abstral Is Ready For Launch In France 32
Jun 30, 2009: ProStrakan Announces Upcoming Launch of Abstral in France 33
Jun 25, 2009: ProStrakan Announces Publication of Notice of Allowance for Sancuso US Patent 33
May 05, 2009: ProStrakan Announces US Submission Of Fortigel (Testosterone) 2% Gel 33
Mar 02, 2009: Orexo’s Abstral Receives Two Further Large EU Market Approvals In France Aand Spain 34
Feb 18, 2009: Orexo signs agreement for Abstral in Israel 35
Feb 09, 2009: ProStrakan Announces Further Outlicensing Deals in Globalisation of Sancuso 35
Jan 27, 2009: Orexo signs agreement for Abstral in China 35
Financial Deals Landscape 37
ProStrakan Group plc, Deals Summary 37
ProStrakan Group plc, Pharmaceuticals & Healthcare, Deal Details 40
Asset Transactions 40
ProStrakan Acquires Abstral From Orexo For $85 Million 40
ProStrakan Acquires Expanded Rights To Rectogesic and Tostran From Cellegy Pharma 42
Private Equity 44
ProStrakan Raise $39.76 Million 44
Partnerships 46
ProStrakan Enters Into Co-Marketing Agreement With EKR Therapeutics 46
ProStrakan Forms Partnership With NovaQuest 47
ProStrakan Signs An Agreement With LG Life Sciences 48
ProStrakan Forms Joint Venture With Orexo 49
ProStrakan Enters Into Distribution Agreement With Gedeon Richter 50
Licensing Agreements 51
Abeille Pharma Enters Into Licensing Agreement With Prostrakan 51
ProStrakan Enters Into Licensing Agreement with Genus Pharma 52
Paladin Labs Enters Into Licensing Agreement With ProStrakan Group 53
Paladin Labs Enters Into Licensing Agreement With ProStrakan 56
ProStrakan Enters Into License Agreement With NewBridge 58
Orexo Extends Its Licensing Agreement With ProStrakan 59
ProStrakan Enters Into Licensing Agreement With JapanBridge 60
ProStrakan Enters Into Licensing Agreement With Torrex Chiesi Pharma 62
ProStrakan Enters Into Licensing And Distribution Agreement With Ferring 63
ProStrakan Enters Into Licensing Agreement With Novartis 64
ProStrakan Enters Into Licensing Agreement With Amgen 65
ProStrakan Amends Licensing Agreement With Cellegy Pharma 66
ProStrakan Enters Into Licensing Agreement With Orexo 67
ProStrakan Amends Licensing Agreement With Cellegy Pharma For Rectogesic 68
ProStrakan Enters Into Licensing Agreement With Cellegy Pharma For Rectogesic 70
Equity Offering 71
ProStrakan Completes Private Placement Of $20.8 Million 71
Asset Transactions 72
ProStrakan Sells Its Product Zindaclin To Crawford Healthcare 72
Acquisition 74
Kyowa Hakko Kirin Completes Acquisition Of ProStrakan 74
Norgine Acquires 12.61% Stake In ProStrakan 78
MDY Healthcare Acquires Minority Stake In ProStrakan Group 80
ProStrakan Group Sells ProSkelia To Galapagos 83
ProStrakan Acquires APS Pharma 85
ProStrakan Acquires Elfar 86
Prostrakan Acquires OTL Pharma 87
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 89
Disclaimer 89

List of Tables
ProStrakan Group plc, Key Information 7
ProStrakan Group plc, Key Facts 7
ProStrakan Group plc – Pipeline by Indication, 2012 9
ProStrakan Group plc – Pipeline by Stage of Development, 2012 10
ProStrakan Group plc – Monotherapy Products in Pipeline, 2012 11
ProStrakan Group plc – Phase III, 2012 12
ProStrakan Group plc – Phase II, 2012 13
ProStrakan Group plc – Pipeline By Therapeutic Class, 2012 20
ProStrakan Group plc - Pipeline By Target, 2012 21
ProStrakan Group plc – Pipeline By Route of Administration, 2012 22
ProStrakan Group plc – Pipeline Products By Mechanism of Action, 2012 23
ProStrakan Group plc – Recent Pipeline Updates, 2012 24
ProStrakan Group plc - Dormant Developmental Projects,2012 26
ProStrakan Group plc, Other Locations 27
ProStrakan Group plc, Subsidiaries 27
ProStrakan Group plc, Deals Summary 37
ProStrakan Acquires Abstral From Orexo For $85 Million 40
ProStrakan Acquires Expanded Rights To Rectogesic and Tostran From Cellegy Pharma 42
ProStrakan Raise $39.76 Million 44
ProStrakan Enters Into Co-Marketing Agreement With EKR Therapeutics 46
ProStrakan Forms Partnership With NovaQuest 47
ProStrakan Signs An Agreement With LG Life Sciences 48
ProStrakan Forms Joint Venture With Orexo 49
ProStrakan Enters Into Distribution Agreement With Gedeon Richter 50
Abeille Pharma Enters Into Licensing Agreement With Prostrakan 51
ProStrakan Enters Into Licensing Agreement with Genus Pharma 52
Paladin Labs Enters Into Licensing Agreement With ProStrakan Group 53
Paladin Labs Enters Into Licensing Agreement With ProStrakan 56
ProStrakan Enters Into License Agreement With NewBridge 58
Orexo Extends Its Licensing Agreement With ProStrakan 59
ProStrakan Enters Into Licensing Agreement With JapanBridge 60
ProStrakan Enters Into Licensing Agreement With Torrex Chiesi Pharma 62
ProStrakan Enters Into Licensing And Distribution Agreement With Ferring 63
ProStrakan Enters Into Licensing Agreement With Novartis 64
ProStrakan Enters Into Licensing Agreement With Amgen 65
ProStrakan Amends Licensing Agreement With Cellegy Pharma 66
ProStrakan Enters Into Licensing Agreement With Orexo 67
ProStrakan Amends Licensing Agreement With Cellegy Pharma For Rectogesic 68
ProStrakan Enters Into Licensing Agreement With Cellegy Pharma For Rectogesic 70
ProStrakan Completes Private Placement Of $20.8 Million 71
ProStrakan Sells Its Product Zindaclin To Crawford Healthcare 72
Kyowa Hakko Kirin Completes Acquisition Of ProStrakan 74
Norgine Acquires 12.61% Stake In ProStrakan 78
MDY Healthcare Acquires Minority Stake In ProStrakan Group 80
ProStrakan Group Sells ProSkelia To Galapagos 83
ProStrakan Acquires APS Pharma 85
ProStrakan Acquires Elfar 86
Prostrakan Acquires OTL Pharma 87

List of Figures
ProStrakan Group plc – Pipeline by Indication, 2012 9
ProStrakan Group plc – Pipeline by Stage of Development, 2012 10
ProStrakan Group plc – Monotherapy Products in Pipeline, 2012 11
ProStrakan Group plc – Pipeline By Therapeutic Class, 2012 19
ProStrakan Group plc - Pipeline By Target, 2012 21
ProStrakan Group plc – Pipeline By Route of Administration, 2012 22
ProStrakan Group plc - Pipeline Products By Mechanism of Action, 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos